Marché mondial du syndrome d'Evans - Tendances et prévisions de l'industrie jusqu'en 2028

Analyse et perspectives du marché : Marché mondial du syndrome d'Evans

Le marché du syndrome d'Evans devrait connaître une croissance exponentielle au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché connaît une croissance de 9,30 % au cours de la période de prévision de recherche mentionnée ci-dessus. Les recherches en cours et les produits en cours d'essais cliniques sont les facteurs de croissance du marché du syndrome d'Evans.

Par exemple,

• L'hôpital universitaire de médecine de Pékin a lancé un essai clinique sur une dose unique d'anticorps anti-CD20 avec bortézomib. Il est utilisé pour le traitement de l'anémie hémolytique auto-immune ou syndrome d'Evans.
• Le Peking Union Medical College Hospital a démarré l'essai clinique sur le tacrolimus qui sera utilisé pour le traitement du syndrome d'Evans, de la cytopénie auto-immune et de l'anémie hémolytique auto-immune.

Le syndrome d'Evans est une maladie rare caractérisée par la production d'anticorps par le système immunitaire de l'organisme qui tue ou détruit les globules rouges, les globules blancs ainsi que les plaquettes. Cela entraîne une diminution de la production de globules rouges, c'est-à-dire une cytopénie. Le syndrome d'Evans est lié à l'association d' une anémie hémolytique auto-immune et d'un purpura thrombopénique idiopathique. Il peut survenir soit lui-même, ce que l'on appelle le syndrome d'Evans primaire, soit en raison d'une autre maladie, ce que l'on appelle le syndrome d'Evans secondaire.

Rise in prevalence of autoimmune disease may drive the Evans syndrome market growth, for instance, according to National Institutes of Health, there are up to 23.5 million that is more than 7% Americans suffering from autoimmune disease. In addition, Evans syndrome cases were increased to 1.8 per million person-years and 21.3 per million persons. Increase in awareness about the autoimmune disease may also drive the Evans syndrome market growth. Recurrence of anemia and thrombocytopenia as well as bleeding and infections may hamper the market growth of Evans syndrome. Side-effects related to the treatment such as use of corticosteroids can lead to high blood pressure, high sugar level and weight gain as well as stem cell transplantation does not work for every patient population and no reports showed that the treatment is effective which may hamper the Evans syndrome market growth.  

Increase in healthcare expenditure and support from the government regarding the research and development are some factors that act as opportunity for the Evans syndrome market growth. The exact reason behind the cause of Evans syndrome is still unknown which act as a challenging factor for the Evans syndrome market growth.   

This Evans syndrome market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the Evans syndrome market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Evans Syndrome Market Scope and Market Size

The Evans syndrome market is segmented on the basis of type, diagnosis, treatment, population type, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the Evans syndrome market is segmented into primary Evans syndrome and secondary Evans syndrome.
• On the basis of diagnosis, the Evans syndrome market is segmented into blood test, bone marrow biopsy, flow cytometry and CT scans. Blood test is further segmented to complete blood count (CBC) and direct antiglobulin test.
• On the basis of treatment, the Evans syndrome market is segmented into corticosteroids, immunosuppressive drugs, monoclonal antibody, blood transfusion, IV immune globulin and stem cell transplantation. Corticosteroids are further segmented to prednisolone. Immunosuppressive drugs are further segmented to 6-mercaptopurine and mycophenolate mofetil. Monoclonal antibody is further segmented to rituximab.
• On the basis of population type, the Evans syndrome market is segmented into adults and children.
• On the basis of end-user, the Evans syndrome market is segmented to research institutes, diagnostic laboratories, hospitals and others.
• On the basis of distribution channel, the Evans syndrome market is segmented into hospitals and others.

Global Evans Syndrome Market Country Level Analysis

Global Evans syndrome market is analysed and market size information is provided by country, type, diagnosis, treatment, population type, end-user and distribution channel as referenced above.

The countries covered in the Evans syndrome market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, America accounts the largest market share because of increase in awareness among the population and rising healthcare expenditure. Europe holds the second largest market share due to support from the government for research and development. Asia-Pacific also shares a market due to increase in patient population related to autoimmune disease and increase in developing healthcare technology.    

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The Evans syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to Evans syndrome market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the Evans syndrome market in the growth period.

Competitive Landscape and Global Evans Syndrome Market Share Analysis

Le paysage concurrentiel du marché du syndrome d'Evans fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais cliniques, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial du syndrome d'Evans.

Les principaux acteurs couverts dans le rapport sur le marché mondial du syndrome d'Evans sont Pfizer Inc., Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, entre autres acteurs nationaux et mondiaux. Les données sur les parts de marché sont disponibles séparément pour le monde, l'Amérique du Nord, l'Europe, l'Asie-Pacifique (APAC), le Moyen-Orient et l'Afrique (MEA) et l'Amérique du Sud. Les analystes de DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.

SKU-60605